REFERENCES
- Decramer M, Celli B, Tashkin D, Pauwels R, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. COPD: J Chron Obstruct Pulm Dis 2004; 1: 303–312
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, Update 2004, GOLD website www.goldcopd.com
- Harrold L, Field T, Gurwitz J. Knowledge, patterns of care, and outcomes of care for generalists and specialists. J Gen Intern Med 1999; 14: 499–511, [INFOTRIEVE], [CSA], [CROSSREF]
- National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59, Suppl. I [CSA] (Either page or author must be supplied)
- O'Connor P. Adding value to evidence-based clinical guidelines. JAMA 2005; 294: 741–743, [INFOTRIEVE], [CSA], [CROSSREF]
- Pauwels R A, Buist A S, Ma P, Jenkins C R, Hurd S S. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive Summary. Respir Care 2001; 46: 798–825, [INFOTRIEVE], [CSA]
- Playfor S. Working with Clinical Guidelines. Current Paediatrics 2000; 10: 81–84, [CSA], [CROSSREF]
- Ramsey S. Suboptimal Medical Therapy in COPD. Exploring the Causes and Consequences. Chest 2000; 117: 33–37, [CSA], [CROSSREF]
- Rutschmann O, Janssens J, Vermeulen B, Sarasin F. Knowledge of Guidelines for the Management of COPD: A Survey of Primary Care Physicians. Respir Med 2004; 98: 932–937, [INFOTRIEVE], [CSA], [CROSSREF]
- Schols A, Wesseling G, Kester A, de Vries G, Mostert R, Slangen J, Wouters E. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337–342, [INFOTRIEVE], [CSA], [CROSSREF]
- The TORCH Study Group. The TORCH (Towards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004; 24: 206–210, [CSA], [CROSSREF]
- Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005; 172: 19–38, [INFOTRIEVE], [CSA], [CROSSREF]
- Vestbo J, Lange P. Can GOLD Stage 0 Provide Information of Prognostic Value in Chronic Obstructive Pulmonary Disease?. Am J Respir Crit Care Med 2002; 166: 329–332, [INFOTRIEVE], [CSA], [CROSSREF]
- Welte T, Behnke M, Piecyk A, Holtmann I, Stechert R, Wolf C, Robra B, Raspe H, Magnussen H. Prevalence of respiratory symptoms and lung function impairment in patients treated by German general practitioners. Eur Respir J 2000; 16: S111, [CSA]
- Woolf S, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527–530, [INFOTRIEVE], [CSA]
- Worth H, Buhl R, Cegla U, Criée C, Gillissen A, Kardos P, Kohler D, Magnussen H, Meister R, Nowak D, Petro W, Rabe K, Schultze-Werninghaus G, Sitter H, Teschler H, Welte T, Wettengel R. Guidelines for the diagnosis and treatment of chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie. Pneumologie 2002; 56: 703–737, [CSA]